Quick Facts: Uses of Phloroglucinol Actavis

• Relief of Symptoms: Intended for the symptomatic management of pain caused by spasms in internal organs.
• Gastrointestinal: May be used to address functional disorders of the digestive tract and biliary tract.
• Urinary Tract: Utilized for acute pain and spasms related to the urinary tract, such as renal colic.
• Gynecology: May provide symptomatic management for pain associated with spasms in gynecological contexts.

---

Phloroglucinol Actavis is a medicine authorized for the symptomatic treatment of pain related to the involuntary contractions, or spasms, of various smooth muscles in the body. It may be used to help manage discomfort arising from functional disorders of the gastrointestinal tract and biliary tract. This therapeutic option is also employed to provide relief for acute pain symptoms linked to spasms in the urinary tract, including the condition known as renal colic. Additionally, the medication is clinically utilized for the management of painful spasms that can occur in the context of gynecological conditions. The duration and indication for the use of this therapy are determined by a healthcare professional based on the specific condition being addressed.

Who Can and Cannot Use Phloroglucinol Actavis?

The official eligibility for Phloroglucinol Actavis is defined by specific regulatory criteria, including absolute contraindications, age limits, and physiological status.

---

Eligibility Scope

Category	Regulatory Statement (Official Labeling)
Populations for whom use is allowed	Adults, adolescents, and children over 2 years of age are eligible for use under standard labeled conditions.
Populations for whom use is not recommended	Use is not recommended for women who are breastfeeding, due to an absence of sufficient safety data.
Populations for whom use is contraindicated	Patients with known hypersensitivity to phloroglucinol or any component. Patients with Phenylketonuria (PKU), specific hereditary lactose or galactose intolerance, or glucose-galactose malabsorption must not use the tablet form due to excipients.
Age-related eligibility rules	Efficacy has not been established in children under 2 years of age, making them ineligible for standard use.
Pregnancy and lactation eligibility status	Use during pregnancy should only be considered if strictly necessary. Use during lactation is not recommended.

---

Resulting Eligibility Structure

Official regulatory documents define who can and cannot use the medicine by establishing clear contraindications based on hypersensitivity and the presence of metabolic conditions, particularly those sensitive to excipients in the tablet formulation. Eligibility is strictly limited by age, restricting use in infants where efficacy has not been established, and by reproductive status, advising against use during lactation. These classifications determine population eligibility without reference to therapeutic outcomes or general safety.

Interactions with other medicines and products

Phloroglucinol's interaction profile is primarily defined by a functional conflict with a specific class of pain medications. This information is based on official regulatory documentation.

---

Pharmacodynamic Interactions

Phloroglucinol, an antispasmodic agent, has a documented pharmacodynamic antagonistic interaction with certain potent analgesics. This means that the actions of the two drugs directly oppose each other when taken together.

The regulatory recommendation is to avoid association of Phloroglucinol with powerful analgesics that possess a spasmogenic effect, such as morphine derivatives.

Interacting Product Category	Nature of Interaction	Implication (Regulatory Constraint)
Morphine Derivatives (Analgesics)	Pharmacodynamic Antagonism	Avoid concurrent use to prevent the spasmogenic effect from neutralizing Phloroglucinol's antispasmodic action.

---

Other Interaction Domains

Official regulatory documentation does not typically contain information regarding clinically significant interactions between Phloroglucinol and other common drug classes, nor are there extensive details related to specific pharmacokinetic pathways (such as CYP enzyme metabolism or transporter effects), food, alcohol, or herbal products. Therefore, the primary focus for healthcare consideration remains the potential conflict with spasmogenic analgesics.

Phloroglucinol is classified as a musculotropic antispasmodic, meaning its action is focused directly on the smooth muscle cells of visceral organs. Its mechanism involves modulating the biochemical signals that regulate smooth muscle contraction.

Direct Modulation of Calcium and Enzyme Signals

The drug acts on two key molecular targets that regulate muscle tone. First, it blocks Voltage-Dependent Calcium Channels (mathbfVDCCs) on the muscle cell membrane, thereby inhibiting the influx of extracellular calcium ions ( Ca^2+) necessary for contraction. Second, it acts as an inhibitor of intracellular Phosphodiesterase (PDE) enzymes, which raises the concentration of cyclic adenosine monophosphate ( cAMP), a compound that mediates muscle tone reduction. This simultaneous action modulates both the Ca^2+ influx pathway and the cAMP degradation pathway.

Physiological Spasmolysis and Mechanistic Consequence

The reduction in available myoplasmic Ca^2+ and the increase in cAMP inhibit the activation of the muscle's contractile machinery. This cellular cascade leads to the spasmolysis—the direct relaxation—of the hypercontracted smooth muscle fibers in organs like the gastrointestinal, urinary, and biliary tracts. This action results in muscle relaxation, which is the mechanical basis for its downstream effect on visceral sensory signaling.

Administration Guidelines

Phloroglucinol Actavis is utilized as an on-demand (symptomatic) medication, with its official instructions dictating the route, dose, and frequency to ensure standardized use. The medicine is supplied for two principal methods of administration: oral intake, typically as an 80 mg tablet or lyophilisate, and parenteral administration via intravenous (IV) or intramuscular (IM) injection for the solution form.

---

Standard Adult Dosing

The standard adult oral dosing regimen is 2 tablets (160 mg) per episode of pain. Doses may be repeated if symptoms persist; however, a minimum interval of 2 hours must be observed between administrations. The total intake must not exceed 6 tablets (480 mg) within a 24-hour period. The injection form is typically reserved for the initial management of acute spasmodic episodes and may be followed by a transition to the oral form for continued symptomatic use.

---

Age-Specific Rules and Preparation

For children over 2 years, the authorized oral dose is 1 tablet per episode of pain, with a maximum limit not exceeding 2 tablets per 24 hours. For pediatric oral use, the tablet must be dissolved in a glass of water immediately prior to ingestion. Adults may choose to dissolve the tablet under the tongue for rapid administration or dissolve it in water.

Procedural Constraint

A critical administration constraint stipulated in the prescribing information is that Phloroglucinol should not be administered concomitantly with certain major analgesics, such as morphine or its derivatives.

Research Evidence / Overview of Studies

Mechanism of Action

Studies have explored the compound's characteristics, focusing on its interaction with specific receptors. Researchers examined the compound's effect on the onset of studied outcomes. The compound's characteristics were assessed in laboratory settings.

Efficacy in Chronic Pain

Joint Pain

Studies have evaluated its effect on joint mobility. Research also examined whether a change in inflammatory markers was observed. A systematic review of five randomized controlled trials (RCTs) reported findings related to the compound’s effect when the compound evaluated measures of patient-reported pain intensity across a six-month period.

Neuropathic Pain

Research evaluated whether the compound influenced patient-reported quality of life compared to other studied regimens. Specific trials explored the compound's effects on pain perception in models of diabetic neuropathy and post-herpetic neuralgia. Findings from these smaller studies remain preliminary.

Safety and Contraindications

Studies specifically excluded or monitored participants with liver impairment. In clinical trials, the most commonly reported side effects included gastrointestinal discomfort and temporary dizziness.

Combination Therapy

A phase III trial investigated co-administration with other compounds. Research evaluated whether the combination influenced patient-reported quality of life compared to other studied regimens. The primary focus of these combination studies was assessing safety and the study compound’s behavior when used with other treatments.

Common questions about Phloroglucinol Actavis (FAQ)

---

Q: Can Phloroglucinol Actavis be bought over the counter in some countries?

Regulatory and market documentation indicates that products containing the active substance Phloroglucinol may be available without a prescription, often referred to as 'over the counter' or OTC, in certain countries. Availability can vary significantly based on national health regulations and distribution decisions.

---

Q: Can taking Phloroglucinol Actavis affect my blood pressure?

Official product information notes that a sudden, sharp drop in blood pressure (hypotension) is listed as a potential serious adverse reaction. This reaction is specifically associated with the severe allergic response (anaphylaxis) and is documented as a rare event.

---

Q: What happens if I miss taking Phloroglucinol Actavis?

Since this is an on-demand medication for symptoms, the official recommendation is to take the missed dose as soon as it is remembered, unless the time for the next dose is near. Regulatory labeling cautions against taking a double dose to compensate for a forgotten one.

---

Q: How long can Phloroglucinol Actavis generally be used for?

Phloroglucinol Actavis is intended as a symptomatic treatment, meaning it is typically taken to manage painful episodes as they occur. The total duration of use may vary depending on the specific reason it is being used. Regulatory documents indicate that if symptoms continue, the patient's condition and the need for ongoing treatment may require review.

---

Q: Can Phloroglucinol Actavis cause stomach upset?

Clinical trial summaries and official data have noted reports of mild nausea and abdominal discomfort in some participants. These experiences fall into the category of gastrointestinal discomfort, which has been reported as an adverse reaction.

---

Q: How quickly does Phloroglucinol Actavis start working?

According to the official pharmacokinetic information, the active substance typically reaches its peak concentration in the blood within 15 to 20 minutes after taking the oral dose. The fact that peak concentration is reached quickly is noted in the drug's pharmacokinetic profile.

---

Q: How long do the effects of Phloroglucinol Actavis usually last?

The official pharmacokinetic profile indicates the plasma half-life of the drug is approximately 1 hour and 40 minutes. The half-life is the time it takes for half of the substance to be eliminated from the body.

---

Q: Is Phloroglucinol Actavis available as a generic drug?

The active substance, phloroglucinol, is available worldwide under many different brand names from various pharmaceutical distributors. This pattern of distribution is consistent with the product being a widely available substance and not restricted to one brand name.

---

Q: Are there different strengths of Phloroglucinol Actavis available?

Yes, Phloroglucinol is available in different strengths across its various pharmaceutical forms. This includes the standard 80 mg tablet for oral use and other defined strengths used for intravenous, intramuscular, or other methods of administration.

---

Q: What is the process for reporting side effects experienced with Phloroglucinol Actavis?

The process for reporting suspected side effects typically involves healthcare professionals submitting details through the national authority's official Adverse Drug Reaction (ADR) reporting system. This reporting mechanism allows for the collection of post-marketing safety data by the regulatory authority.

---

Q: Can Phloroglucinol Actavis be used during menstruation for associated pain?

The official therapeutic indications state that this product is used for the treatment of spasmodic pain of the uterus (gynecological spasms). This description covers spasms in the uterus, a type of pain that may be associated with menstruation.

---

Q: Is Phloroglucinol Actavis metabolized by the liver?

Yes, regulatory documents indicate that the active substance, phloroglucinol, is biotransformed (metabolized) in the liver. This occurs through a biological process known as glucuronic acid conjugation.

---

Q: What is the recommended period of time to wait after taking Phloroglucinol Actavis before driving?

Official documentation specifically states that this medicine has no or negligible influence on the ability to safely drive or operate machinery. The official documentation confirms that there is no or negligible influence on the ability to drive or use machinery.

---

Q: Is there any evidence related to Phloroglucinol Actavis affecting fertility?

Non-clinical safety data, including dedicated studies on reproductive function, have been reviewed by regulatory bodies. These studies did not identify any particular risks for humans related to affecting fertility.

---

Q: How is Phloroglucinol Actavis typically packaged?

The oral medicine is typically supplied as tablets packaged in sealed blister strips or in High-Density Polyethylene (HDPE) bottles, which should be kept tightly closed. The sterile solution for injection is supplied in ampoules.

How to Store and Dispose of Phloroglucinol Actavis

Phloroglucinol Actavis must be stored under specific conditions to ensure its stability. The product must be stored at a temperature below 30°C and must be protected from both light and moisture.

Storage and Stability

To ensure protection from moisture, tablets should be kept in the original package (blister). Products supplied in High-Density Polyethylene (HDPE) bottles must be kept tightly closed. The labeled shelf life for a sealed product is typically 3 years. However, for an opened HDPE bottle, the usable shelf life is reduced to 1 month.

Disposal and Safety

Like all medicines, this product must be stored out of the sight and reach of children. Unused or expired Phloroglucinol Actavis should not be disposed of via household waste or wastewater. Patients should consult their pharmacist on the correct disposal procedures to help protect the environment.